-
-
-
-
-
-
-
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
-
-
-
-
-
-
-
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
-
-
-
-
-
-
-
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
-
-
-
-
-
-
-
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
-
-
-
-
-
-
-
CASI Pharmaceuticals Announces Full Year 2020 Financial Results
-
-
-
-
-
-
-
CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
-
-
-
-
-
-
-
CASI Pharma (CASI) Reports Acquisition of ANDA Portfolio From Sandoz Inc.
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

